Imatinib is used to treat Chronic Myeloid Leukemia (CML) patients who express a constitutively active c-Abl tyrosine kinase, the BCR-ABL fusion protein. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.